Patient enrollment in HDL therapy clinical trial approaches completion after FDA approved expansion

摘要

Lipid Sciences Inc.reported that enrollment is complete for two-thirds,or 20 out of a total target of 30 patients,in the Company's safety and feasibility clinical trial of 'HDL Selective Delipidation' at the Washington Hospital Center in Washington,D.C.The FDA approval to add three additional hospital sites for this clinical trial in the Washington,D.C.area will increase the pool of eligible participants and move the company closer to its goal of completing the clinical trial by the end of the year,said President and Chief Executive Officer,Dr.S.Lewis Meyer.